Editors ’ Picks

Recent clinical trials demonstrated the efficacy of novel biologics as metastatic melanoma treatments. These drugs include ipilimumab, an antibody that targets CTLA4 as well as pembrolizumab and nivolumab, antibodies that target programmed death 1 (PD-1). Following approval of ipilimumab and nivolumab as effective agents for adjuvant therapy, Eggermont and colleagues initiated a study to compare pembrolizumab treatment with matching placebo as adjuvant therapy for patients with  resected, high-risk stage III melanoma.
Source: Journal of Investigative Dermatology - Category: Dermatology Tags: Editorial Source Type: research